Compare Abeona Therapeutics Inc (ABEO) vs Macy's Inc (M) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Macy's Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Macy's Inc trades at $22.46 (market cap $6.08B). The key difference: Macy's Inc is far larger — about 16.3× Abeona Therapeutics Inc's market cap, and Macy's Inc pays a 3.31% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | M | |
|---|---|---|
Market Cap | $373.32M | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $25.96 |
52-Week Low | $4.17 | $11.90 |
Enterprise Value | $228.22M | $9.90B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Macy's (M) trades at $23.13, down 0.52% on the day, with technical indicators showing a bullish trend supported by moving averages. The stock shows attractive valuation metrics with a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. The company's 'Bold New Chapter' strategy is gaining traction with improved comparable sales and digital growth, supported by Berkshire Hathaway's new 3.04 million-share position disclosed in Q1 2026.
Macy's presents a compelling value opportunity with strong institutional interest and operational improvements, though investors face risks from retail sector headwinds and margin pressure. The consensus price target of $23.80 suggests modest upside potential, while execution on turnaround initiatives remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
